All‐trans retinoic acid and arsenic combination therapy benefits low‐to‐intermediate‐risk patients with newly diagnosed acute promyelocytic leukaemia: a long‐term follow‐up based on multivariate analysis. (30th March 2015) - Zhu, Hongming